Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : biotech firesales -- Ignore unavailable to you. Want to Upgrade?

To: Ian@SI who wrote (2164)	11/10/2008 5:59:16 PM
From: RockyBalboa	Respond to of 3661

nice... sgmo down another 15% to 2.45, eat what you kill, or kill what you can eat....

To: Ian@SI who wrote (2164)	11/18/2008 8:44:40 AM
From: RockyBalboa	Read Replies (2) \| Respond to of 3661

Total crash in XTLB -97% to $0.06 (was 2.23) . Go figure! Press Release Source: XTL Biopharmaceuticals Ltd. XTL Biopharmaceuticals Announces Top-Line Results From the Bicifadine Phase 2b Study for Diabetic Neuropathic Pain Tuesday November 18, 8:05 am ET Study failed to meet its primary endpoint VALLEY COTTAGE, N.Y., Nov. 18 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB; TASE: XTL) announced today the top-line results from the Bicifadine Phase 2b clinical trial for the treatment of diabetic neuropathic pain. The trial's primary objective was to compare the efficacy of two doses of Bicifadine against placebo in reducing pain associated with diabetic neuropathy. The primary endpoint of the study was the reduction in pain score during the course of treatment. The company announced that the study failed to meet its primary endpoint. The trial also failed to meet key secondary analysis. Ron Bentsur, CEO of the company, commented: "We are all very disappointed with the results of the study. We will devote the next few days to further analyze the data and decide on the appropriate course of action for the Bicifadine program, and for the company." -------------------------------------------------------------------------------- Source: XTL Biopharmaceuticals Ltd.